Silverback Therapeutics Inc logo

SBTX - Silverback Therapeutics Inc Share Price

n/a 0.0  0.0%

Last Trade -

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6444
Bullish
Bearish
Unlock SBTX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Silverback Therapeutics Inc revenues was not reported. Netloss increased 17% to $19.9M. Higher net loss reflectsPHARMACEUTICAL PREPARATIONS segment loss increase of 16% to$19.8M. Basic Earnings per Share excluding ExtraordinaryItems decreased from -$0.21 to -$0.25.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SBTX Revenue Unlock SBTX Revenue

Net Income

SBTX Net Income Unlock SBTX Revenue

Normalised EPS

SBTX Normalised EPS Unlock SBTX Revenue

PE Ratio Range

SBTX PE Ratio Range Unlock SBTX Revenue

Dividend Yield Range

SBTX Dividend Yield Range Unlock SBTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SBTX EPS Forecasts Unlock SBTX Revenue
Profile Summary

Silverback Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on ImmunoTAC technology platform to develop therapeutics for the treatment of cancer, chronic viral infections, and other diseases. Its ImmunoTAC platform includes three components, such as Antigen binding domain, Linker-payload, and Fc region. Its lead product candidate, SBT6050, is comprised of a Toll-like receptor 8 (TLR8) agonist linker-payload conjugated to a human epidermal growth factor receptor 2 (HER2)-directed monoclonal antibody that targets tumors including certain breast, gastric and non-small cell lung cancers. Its second product candidate, SBT6290, is comprised of a TLR8 agonist as a payload. SBT6290 is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4. Its third TLR8 program, SBT8230, is comprised of a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is for the treatment of chronic hepatitis B virus infection (cHBV).

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 4, 2016
No. of Shareholders: n/a
No. of Employees: 52
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Market
Shares in Issue 80,077,283
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SBTX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SBTX
Upcoming Events for SBTX
Frequently Asked Questions for Silverback Therapeutics Inc
What is the Silverback Therapeutics Inc share price?

As of , shares in Silverback Therapeutics Inc are trading at n/a, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Silverback Therapeutics Inc share price performed this year?

Shares in Silverback Therapeutics Inc are currently trading at n/a and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Silverback Therapeutics Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Silverback Therapeutics Inc?

There are no analysts currently covering Silverback Therapeutics Inc.

When will Silverback Therapeutics Inc next release its financial results?

Silverback Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Silverback Therapeutics Inc dividend yield?

Silverback Therapeutics Inc does not currently pay a dividend.

Does Silverback Therapeutics Inc pay a dividend?

Silverback Therapeutics Inc does not currently pay a dividend.

When does Silverback Therapeutics Inc next pay dividends?

Silverback Therapeutics Inc does not currently pay a dividend.

How do I buy Silverback Therapeutics Inc shares?

To buy shares in Silverback Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Silverback Therapeutics Inc?

Shares in Silverback Therapeutics Inc are currently trading at n/a, giving the company a market capitalisation of £n/a.

Where are Silverback Therapeutics Inc shares listed? Where are Silverback Therapeutics Inc shares listed?

Here are the trading details for Silverback Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: SBTX
What kind of share is Silverback Therapeutics Inc?

We were not able to load our ranking data for Silverback Therapeutics Inc

Is there a Silverback Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for Silverback Therapeutics Inc.

How can I tell whether the Silverback Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Silverback Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of n/a, shares in Silverback Therapeutics Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Silverback Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Silverback Therapeutics Inc.

Who are the key directors of Silverback Therapeutics Inc?

Silverback Therapeutics Inc's management team is headed by:

Laura Shawver - PRE
Peter Thompson - CHM
Valerie Odegard - CSO
Russ Hawkinson - SVF
Naomi Hunder - SVP
Who are the major shareholders of Silverback Therapeutics Inc?

Here are the top five shareholders of Silverback Therapeutics Inc based on the size of their shareholding:

Similar to SBTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.